Challenges in Treating TRK Fusion Cancer

Article

At the ESMO Congress 2019, Ulrik Lassen, MD, PhD, oncology professor at the University of Copenhagen explained the challenges in identifying and treating TRK fusion cancer in patients.

At the ESMO Congress 2019, Ulrik Lassen, MD, PhD, oncology professor at the University of Copenhagen explained the challenges in identifying and treating TRK fusion cancer in patients.

Transcript

TRK [tropomyosin receptor kinase] fusion cancer is quite rare in the common cancers. We don’t know the exact incidence, but we believe it is below 1%. So it is very difficult to find in the common cancers and we need some strategies of how to identify the patients. But then it’s very frequent in some very rare cancer, so this also complicates it. But we know, for instance, in infantile fibrosarcoma and secondary breast cancer it’s almost pathognomonic so It’s needed to state the diagnosis.

Recent Videos
Naloxone concept represented by wooden letter tiles.
Hand holding a Narcan Evzio Naloxone nasal spray opioid drug overdose prevention medication
Image credit:  Gorodenkoff | stock.adobe.com
Pharmacist and Patient in Pharmacy | Image Credit: Gorodenkoff - stock.adobe.com
Catalyst Trial, Diabetes, Hypertension | Image Credit: grinny - stock.adobe.com
Image Credit: © Anastasiia - stock.adobe.com
Various healthy foods -- Image credit: New Africa | stock.adobe.com
LGBTQIA+ pride -- Image credit: lazyllama | stock.adobe.com
© 2024 MJH Life Sciences

All rights reserved.